3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
25
Pancreatic Neoplasms
17
Neoplasm Metastasis
14
Neuroblastoma
7
Rhabdomyosarcoma
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Neoplasms
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma, Ewing
4
Sarcoma
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Wilms Tumor
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Colorectal Adenocarcinoma
2
Cholangiocarcinoma
2
Carcinoma, Neuroendocrine
2
Breast Neoplasms
2
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled